CDK9 and acute myeloid leukemia: Therefore, we tested the sensitivity of two t(8;21)-containing AML cell lines, SKNO-1 (Figure 1A–E) and Kasumi-1 (Figure 1F), to flavopiridol (FVP, broad spectrum CDK inhibitor), dinaciclib (Dina, a more potent broad spectrum CDK inhibitor), PHA767491 (PHA, a more selective CDK9 inhibitor), THZ1 (CDK7 inhibitor) and palbociclib (palbo, CDK4/6 inhibitor).